SUN Pharma has signed an exclusive worldwide licensing deal with Israeli firm Moebius Medical to further develop MM-II, a "novel pharmaceutical candidate for the treatment of pain in osteoarthritis".
MM-II is a novel non-opioid product which leverages the physical properties of proprietary liposomes to lubricate arthritic knee joints, reducing friction and consequently joint pain.
Under the agreement Sun Pharma will fund further development of MM-II and undertake its global commercialisation.
The first human clinical study showed the product's "fast onset of action and its potentially better efficacy and comparable safety for alleviating osteoarthritis pain as compared to Hyalonuric Acid injection".
The above article was sent to subscribers in Pharmacy Daily's issue from 14 Dec 16
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 14 Dec 16
